scholarly journals Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review

2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Ran Cheng ◽  
Zhiwu Wu ◽  
Mingming Li ◽  
Meiying Shao ◽  
Tao Hu
Keyword(s):  
Therapeutic Target ◽  
Type Ii Diabetes ◽  
Inflammatory Cytokine ◽  
Clinical Evidence ◽  
Type Ii Diabetes Mellitus ◽  
Therapeutic Strategies ◽  
Type Ii ◽  
Potential Therapeutic Target ◽  
Inflammatory Reactions ◽  
Future Potential

AbstractInterleukin(IL)-1β, a pro-inflammatory cytokine, was elevated and participates in periodontitis. Not only the link between IL-1β and periodontitis was proved by clinical evidence, but also the increased IL-1β triggers a series of inflammatory reactions and promotes bone resorption. Currently, IL-1β blockage has been therapeutic strategies for autoimmune and autoinflammatory diseases such as rheumatoid arthritis, cryopyrin-associated periodic syndromes, gout and type II diabetes mellitus. It is speculated that IL-1β be a potential therapeutic target for periodontitis. The review focuses on the production, mechanism, present treatments and future potential strategies for IL-1β in periodontitis.

scholarly journals The Nrf2/Keap1/ARE Pathway and Oxidative Stress as a Therapeutic Target in Type II Diabetes Mellitus

2017 ◽  
Vol 2017 ◽  
pp. 1-15 ◽  
Author(s):  
Joshua A. David ◽  
William J. Rifkin ◽  
Piul S. Rabbani ◽  
Daniel J. Ceradini
Keyword(s):  
Diabetes Mellitus ◽  
Oxidative Damage ◽  
Therapeutic Target ◽  
Type Ii Diabetes ◽  
Animal Studies ◽  
Cell Types ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
And Oxidative Stress

Despite improvements in awareness and treatment of type II diabetes mellitus (TIIDM), this disease remains a major source of morbidity and mortality worldwide, and prevalence continues to rise. Oxidative damage caused by free radicals has long been known to contribute to the pathogenesis and progression of TIIDM and its complications. Only recently, however, has the role of the Nrf2/Keap1/ARE master antioxidant pathway in diabetic dysfunction begun to be elucidated. There is accumulating evidence that this pathway is implicated in diabetic damage to the pancreas, heart, and skin, among other cell types and tissues. Animal studies and clinical trials have shown promising results suggesting that activation of this pathway can delay or reverse some of these impairments in TIIDM. In this review, we outline the role of oxidative damage and the Nrf2/Keap1/ARE pathway in TIIDM, focusing on current and future efforts to utilize this relationship as a therapeutic target for prevention, prognosis, and treatment of TIID.

Efficiency of the new metabolic operation in treatment of type II diabetes mellitus

2018 ◽  
Vol 24 (2) ◽  
pp. 16-20
Author(s):  
V.V. Grubnik ◽  
◽  
V.V. Ilyashenko ◽  
O.V. Medvedev ◽  
S.O. Usenok ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type Ii Diabetes ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii
Sign in / Sign up

Export Citation Format

Share Document